ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) Andrew Wagner (Dana-Farber Cancer…
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) Andrew Wagner (Dana-Farber Cancer…
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) David Reardon, MD, director…
Real-world data shows that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related…
For cancer survivors experiencing overall mood disturbance, anxiety, fatigue, or insomnia, regular gentle hatha and…
A new study based in Italy found that fasting before and after chemotherapy sessions, when…
Results from the phase 2 ARACOG study, the first direct comparison of the cognitive effects…
A phase I clinical trial is testing whether a tumour-targeting virus can help immunotherapy work…
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are…
Results from the phase 3 KEYNOTE-B15 clinical trial found that the combination of the targeted…
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under…